Stockscreener 앱 받기
53.00
0.40%
-0.2396
전일 마감가:
$53.24
열려 있는:
$53.24
하루 거래량:
239.06K
Relative Volume:
0.34
시가총액:
$4.08B
수익:
$754.05M
순이익/손실:
$73.06M
주가수익비율:
58.42
EPS:
0.9073
순현금흐름:
$164.23M
1주 성능:
-0.58%
1개월 성능:
+23.93%
6개월 성능:
+24.66%
1년 성능:
+97.21%
1일 변동 폭
$52.26
$53.55
1주일 범위
$52.26
$55.33
52주 변동 폭
$26.27
$59.87
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
53.02 | 4.10B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
15.94 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.25 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.65 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.68 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
575.64 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-09-29 | 개시 | TD Cowen | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
UBS Group AG Purchases 28,099 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (KNSA) price target increased by 10.10% to 63.53 - MSN
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Vanguard Group Inc. Acquires 49,802 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month HighStill a Buy? - MarketBeat
Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat - MSN
Kiniksa Pharmaceuticals International : 2025 Annual Report - marketscreener.com
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Why Kiniksa Pharmaceuticals International stock raced nearly 24% higher today - MSN
FMR LLC amends filing showing 6,787,700.23 Kiniksa holdings (KNSA) - Stock Titan
Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next - simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 58,424 Shares - MarketBeat
Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Kornitzer Capital Management Inc. KS Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026) - Minichart
Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance - Yahoo Finance
Sanj Patel Sells 48,565 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor - TipRanks
Kiniksa Pharmaceuticals (KNSA) insider sale notice lists 58,424 shares - Stock Titan
Kiniksa (NASDAQ: KNSA) CSO Tessari resigns, signs $450/hour consulting deal - Stock Titan
Kiniksa (NASDAQ: KNSA) CEO Sanj K. Patel exercises options, sells 48,565 shares under 10b5-1 plan - Stock Titan
KNSA SEC FilingsKiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms - Stock Titan
Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results - Insider Monkey
Kiniksa Pharmaceuticals International, plc Announces Executive Changes - marketscreener.com
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,217,601.44 in Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $115,635.41 in Stock - MarketBeat
Sanj Patel Sells 483,654 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa (NASDAQ: KNSA) CEO’s plan-based option exercises and 508K share sales detailed - Stock Titan
Pictet Asset Management Holding SA Has $32.49 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
KNSA Maintained by Citigroup -- Price Target Raised to $60 - GuruFocus
KNSA Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $656,260, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 13,099 Shares of Stock - MarketBeat
Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan - Stock Titan
KNSA Maintained by Wedbush -- Price Target Raised to $59.00 - GuruFocus
Kiniksa Pharmaceuticals International, plc (KNSA) tops Q1 earnings and revenue estimates - MSN
KNSA Maintained by Wells Fargo -- Price Target Raised to $57 - GuruFocus
Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price - MarketBeat
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation (KNSA) - Seeking Alpha
9 Best Drug Stocks to Buy According to Analysts - Insider Monkey
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earning - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High Following Strong Earnings - MarketBeat
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kiniksa Pharmaceuticals International Plc 주식 (KNSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Paolini John F. | CHIEF MEDICAL OFFICER |
May 01 '26 |
Sale |
53.71 |
58,424 |
3,137,823 |
65,623 |
1.38%
1.89%
자본화:
|
볼륨(24시간):